Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) just unveiled an announcement.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that its enoxaparin sodium injection, Enoparin, has received approval from Argentina’s National Administration of Drugs, Food and Medical Devices for market sales. This approval is expected to enhance the company’s global market share and demonstrates its capability to penetrate international markets, supporting its strategy to expand its global footprint and strengthen its sales channels.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company is known for its enoxaparin sodium injection, marketed under the name Enoparin, which is used for various medical indications including prevention and treatment of thromboembolic diseases.
YTD Price Performance: 16.92%
Average Trading Volume: 2,155,232
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$16.96B
See more data about 9989 stock on TipRanks’ Stock Analysis page.